We also extended into a proof-of-principle tumor xenograft model whereby GC parental and GC resistant organoids were injected subcutaneously into immunocompromised mice and treated with DMSO or 5FU + CDDP and vehicle or SCD1 inhibitor SSI4 (Fig. 5c). The gene discussed is SCD; the disease is neoplasm.